Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies

Abstract Background Patients with metastatic breast cancer (MBC) are living longer, but development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population. Methods Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to: breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with HER2+, triple negative, and hormone receptor (HR)+/HER2- MBC; pooled overall estimates for incidence were calculated using random effects models. Results 937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2- MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0 – 34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5 – 40.6), and 15% among patients with HR+/HER2- MBC (median follow-up: 33.0 months, IQR: 31.9 – 36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10 – 0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09 – 0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03 – 0.08) for patients with HR+/HER2- MBC. Conclusion There is high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations.

Download Full-text

Impact of postoperative complications on long-term outcomes of patients following surgery for gastric cancer: A systematic review and meta-analysis of 64 follow-up studies

Asian Journal of Surgery ◽

10.1016/j.asjsur.2019.10.007 ◽

2020 ◽

Vol 43 (7) ◽

pp. 719-729

Author(s):

Jian Li ◽

Yao Zhang ◽

Deng-Min Hu ◽

Tu-Ping Gong ◽

Run Xu ◽

...

Keyword(s):

Gastric Cancer ◽

Systematic Review ◽

Postoperative Complications ◽

Meta Analysis ◽

Long Term Outcomes ◽

Follow Up Studies

Download Full-text

Long-Term Effects of Oral Antidiabetic Drugs During Pregnancy on Offspring: A Systematic Review and Meta-analysis of Follow-up Studies of RCTs

Diabetes Therapy ◽

10.1007/s13300-018-0479-0 ◽

2018 ◽

Vol 9 (5) ◽

pp. 1811-1829 ◽

Cited By ~ 16

Author(s):

Wenneke van Weelden ◽

Vincent Wekker ◽

Leon de Wit ◽

Jacqueline Limpens ◽

Hilkka Ijäs ◽

...

Keyword(s):

Systematic Review ◽

Meta Analysis ◽

Antidiabetic Drugs ◽

Long Term Effects ◽

Oral Antidiabetic Drugs ◽

Oral Antidiabetic ◽

Follow Up Studies

Download Full-text

Association between metabolic syndrome and venous thromboembolism after total joint arthroplasty: a meta-analysis of cohort studies

Journal of Orthopaedic Surgery and Research ◽

10.1186/s13018-020-02097-4 ◽

2020 ◽

Vol 15 (1) ◽

Author(s):

Yipei Yang ◽

Ziyue Li ◽

Haifeng Liang ◽

Jing Tian

Keyword(s):

Metabolic Syndrome ◽

Cohort Studies ◽

Meta Analysis ◽

Random Effect ◽

Random Effect Model ◽

Joint Arthroplasty ◽

Effect Model ◽

Increased Risk ◽

Subgroup Analyses

Abstract Objective Metabolic syndrome (MetS) has been associated with hypercoagulative status. However, previous studies evaluating the association between MetS and incidence of venous thromboembolism (VTE) after total joint arthroplasty (TJA) showed inconsistent results. We performed a meta-analysis to evaluate the influence of MetS on the risk of VTE following TJA. Methods Cohort studies were identified by the search of PubMed, Embase, and the Cochrane’s Library databases. A random-effect model was used if considerable heterogeneity was detected; otherwise, a fixed-effect model was used. Subgroup analyses according to the category of VTE, definition of MetS, category of procedure, and follow-up durations were performed. Results Seven cohort studies with 1,341,457 patients that underwent TJA were included, with 118,060 MetS patients (8.8%) at baseline. With a follow-up duration up to 3 months after surgery, 9788 patients had VTE. Pooled results with a random-effect model showed that MetS was not associated with increased overall VTE after TJA (adjusted risk ratio [RR] = 1.24, 95% confidence interval [CI] 0.89 ~ 1.72, p = 0.20; I2 = 69%). The results were not significantly affected by the diagnostic criteria of MetS, category of the procedure, and follow-up durations. Subgroup analyses showed that MetS was not associated with an increased the risk of pulmonary embolism ([PE], RR 1.06, 95% CI 0.37 ~ 3.02, p = 0.91), but an increased risk of deep vein thrombosis (DVT) after TJA (RR 3.38, 95% CI 1.83 ~ 6.24, p < 0.001). Conclusions Current evidence from observational studies suggests MetS might be associated with an increased risk of DVT but not PE after TJA.

Download Full-text

Intuitions About the Reference of Proper Names: a Meta-Analysis

Review of Philosophy and Psychology ◽

10.1007/s13164-020-00503-8 ◽

2020 ◽

Author(s):

Noah van Dongen ◽

Matteo Colombo ◽

Felipe Romero ◽

Jan Sprenger

Keyword(s):

Experimental Philosophy ◽

Meta Analysis ◽

Proper Names ◽

Cross Cultural ◽

Cultural Effects ◽

Follow Up Studies

Abstract The finding that intuitions about the reference of proper names vary cross-culturally (Machery et al. Cognition 92: 1–12. 2004) was one of the early milestones in experimental philosophy. Many follow-up studies investigated the scope and magnitude of such cross-cultural effects, but our paper provides the first systematic meta-analysis of studies replicating (Machery et al. Cognition 92: 1–12. 2004). In the light of our results, we assess the existence and significance of cross-cultural effects for intuitions about the reference of proper names.

Download Full-text

Assessing Sex Differences in the Risk of Cardiovascular Disease and Mortality per Increment in Systolic Blood Pressure: A Systematic Review and Meta-Analysis of Follow-Up Studies in the United States

PLoS ONE ◽

10.1371/journal.pone.0170218 ◽

2017 ◽

Vol 12 (1) ◽

pp. e0170218 ◽

Cited By ~ 26

Author(s):

Yu-Chung Wei ◽

Nysia I. George ◽

Ching-Wei Chang ◽

Karen A. Hicks

Keyword(s):

United States ◽

Systematic Review ◽

Blood Pressure ◽

Cardiovascular Disease ◽

Sex Differences ◽

Systolic Blood Pressure ◽

Meta Analysis ◽

The United States ◽

Follow Up Studies

Download Full-text

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2007.10.8399 ◽

2008 ◽

Vol 26 (12) ◽

pp. 1980-1986 ◽

Cited By ~ 138

Author(s):

Martine J. Piccart-Gebhart ◽

Tomasz Burzykowski ◽

Marc Buyse ◽

George Sledge ◽

James Carmichael ◽

...

Keyword(s):

Breast Cancer ◽

Meta Analysis ◽

Single Agent ◽

Metastatic Breast ◽

Progression Free Survival ◽

Response Rates ◽

First Line ◽

First Line Therapy ◽

Hazard Ratios

Purpose Taxanes (paclitaxel or docetaxel) have been sequenced or combined with anthracyclines (doxorubicin or epirubicin) for the first-line treatment of advanced breast cancer. This meta-analysis uses data from all relevant trials to detect any advantages of taxanes in terms of tumor response, progression-free survival (PFS), and survival. Patients and Methods Individual patient data were collected on eight randomized combination trials comparing anthracyclines + taxanes (+ cyclophosphamide in one trial) with anthracyclines + cyclophosphamide (+ fluorouracil in four trials), and on three single-agent trials comparing taxanes with anthracyclines. Combination trials included 3,034 patients; single-agent trials included 919 patients. Results Median follow-up of living patients was 43 months, median survival was 19.3 months, and median PFS was 7.1 months. In single-agent trials, response rates were similar in the taxanes (38%) and in the anthracyclines (33%) arms (P = .08). The hazard ratios for taxanes compared with anthracyclines were 1.19 (95% CI, 1.04 to 1.36; P = .011) for PFS and 1.01 (95% CI, 0.88 to 1.16; P = .90) for survival. In combination trials, response rates were 57% (10% complete) in taxane-based combinations and 46% (6% complete) in control arms (P < .001). The hazard ratios for taxane-based combinations compared with control arms were 0.92 (95% CI, 0.85 to 0.99; P = .031) for PFS and 0.95 (95% CI, 0.88 to 1.03; P = .24) for survival. Conclusion Taxanes were significantly worse than single-agent anthracyclines in terms of PFS, but not in terms of response rates or survival. Taxane-based combinations were significantly better than anthracycline-based combinations in terms of response rates and PFS, but not in terms of survival.

Download Full-text